Exposure to gastric acid-suppression therapy is associated with health care- and community-associated clostridium difficile infection in children

Journal of Pediatric Gastroenterology and Nutrition

Volumn 61, Issue 2, 2015, Pages 208-211

  Jimenez, Jennifer ^a   Drees, Marci ^b   Loveridge Lenza, Beth ^a   Eppes, Stephen ^c   DelRosario, Fernando ^d  

^a JERSEY SHORE UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Medicine ^*  (United States)

^c CHRISTIANA CARE HEALTH SYSTEM   (United States)

^d NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

Clostridium difficile infection; Gastric acid suppression therapy; Proton pump inhibitors

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; PROTON PUMP INHIBITOR; ANTACID AGENT; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; CHILD; CHILDHOOD DISEASE; CLINICAL EVALUATION; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY CARE; COMORBIDITY; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DRUG EXPOSURE; FEMALE; GASTRIC ACID SUPPRESSION THERAPY; HEALTH CARE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NONHUMAN; OUTPATIENT CARE; PEDIATRIC HOSPITAL; POPULATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STOMACH ACID; TERTIARY HEALTH CARE; AGE; BLACK PERSON; CAUCASIAN; CHEMICALLY INDUCED; ENTEROCOLITIS, PSEUDOMEMBRANOUS; INFANT; ISOLATION AND PURIFICATION; ODDS RATIO; OUTPATIENT; PEPTOCLOSTRIDIUM DIFFICILE; PRESCHOOL CHILD; RISK FACTOR; TERTIARY CARE CENTER; UNITED STATES;

ADOLESCENT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; ANTACIDS; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GASTRIC ACID; HUMANS; INFANT; INPATIENTS; ODDS RATIO; OUTPATIENTS; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; RISK FACTORS; TERTIARY CARE CENTERS; UNITED STATES;

EID: 84942599437     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0000000000000790     Document Type: Article

References (19)

1. Nylund C, Goudie A, Garza J, et al. Clostridium difficile infection in hospitalized children in the United States. Arch Pediatr Adolesc Med 2011;165:E1-7.
2. Zilberberg MD, Tillotson GS, McDonald LC. Clostridium difficile infections among hospitalized children, United States, 1997-2006. Emerg Infect Dis 2010;16:604-9.
3. Kelly CP, LaMont JT. Clostridium difficile-more difficult than ever. N Engl J Med 2008;359:1932-40.
4. Khanna S, Pardi DS, Aronson SL, et al. The epidemiology of community-acquired Clostridium difficile infection: a population-based study. Am J Gastroenterol 2012;107:89-95.
5. Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31:431-55.
6. Dial S, Delaney JAC, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294:2989-95.
7. Dubberke ER, Reske KA, Yan Y, et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007;45:1543-9.
8. Janarthanan S, Ditah I, Phil M, et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012;107:1001-10.
9. Kwok CS, Arthur AK, Anibueze CI, et al. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012;107:1011-9.
10. Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. Alimet Pharmacol Ther 2009;31:754-9.
11. Hassell E. Over-prescription of acid-suppressing medications in infants: how it came about, why it's wrong, and what to do about it. J Pediatr 2012;160:193-8.
12. Alcala L, Sanchez-Cambronero L, Catalan MP, et al. Comparison of three commercial methods for rapid detection of Clostridium difficile toxins A and B from fecal specimens. J Clin Microbiol 2008;46:3833-5.
13. McDonald LC, Coignard B, Dubberke E, et al. Recommendations for surveillance of Clostridium-difficile-associated disease. Infect Control Hosp Epi 2007;28:140-5.
14. Aseeri M, Schroeder T, Kramer J. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-Associated diarrhea in hospitalized patients. Am J Gastroenterol 2008;103:2308-13.
15. Kaur S, Vaishnavi C, Prasad KK, et al. Comparative role of antibiotic and proton pump inhibitor in experimental Clostridium difficile infection in mice. Microbiol Immunol 2007;51:1209-14.
16. McFarland LV, Brandmarker SA, Guandalini S. Pediatric Clostridium difficile: a phantom menace or clinical reality. J Pediatr Gastroenterol Nutr 2000;31:220-31.
17. Schutze GE, Willoughby RE. Committee on Infectious Diseases; American Academy of Pediatrics. Clostridium difficile infectionin infants and children. Pediatrics 2013;131:196-200.
18. Yanni SB, Annaert PP, Augustijns P, et al. In vitro hepatic metabolism explains higher clearance of voriconazole in children versus adults: role of CYP2C19 and flavin-containing monooxygenase 3. Drug Metab Dispos 2010;38:25-31.
19. Ringel-Kulka T, Cheng J, Ringel Y, et al. Intestinal microbiota in healthy U.S. young children and adults - A high throughput microarray analysis. PLoS ONE 2013;8:1-10.